Syntaxin Ltd.
This article was originally published in Start Up
Executive Summary
Syntaxin is developing bacterial-based biotherapeutic proteins that control cell secretion as potential treatments for neurological, respiratory and metabolic diseases. A team of 13 scientists spun Syntaxin out from the UK's Health Protection Agency (HPA) in November 2005.